Clariant reiterates commitment to pharma
German fine chemicals group Clariant has reaf-firmed its commitment to its pharmaceuticals business and will retain it within the Clariant umbrella of chemicals operations where it can be developed further to achieve the greatest increase in value.
It says the pharmaceutical business represents an essential component of Clariant's continuing activities and that the first signs of positive results are now being seen from the implementation of its new strategy for the business that was begun in 2002. The restructuring of this business unit has been accomplished by site closures and site sales, which had been completed earlier this year.
The pharmaceuticals business will next focus on growth by serving as a supplier to the pharmaceutical industry in the areas of active pharmaceutical ingredients (APIs) and regulated intermediates. Clariant will continue as a leading developer of APIs, new active substances, generics and regulated intermediates, with global marketing, innovative r&d and highly tailored cGMP production.